PackGene is a world-leading adeno-associated virus (AAV) vector CRO and CDMO company. PackGene provides reliable, scalable, and economical plasmid DNA and AAVs ideal for early-stage therapeutic discovery, preclinical development, and clinical trials for in Gene and Cell Therapies. PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform combines a uniquely designed RC plasmid with a triple-plasmid transfection system to increase AAV production by 3 to 8 times that of traditional platforms. By combining both in-process upstream and downstream Quality by Design optimizations we are able to further increase total AAV yield up to 10 fold. Through this unique combination of proprietary platform technology and process optimization a single run of AAV production at PackGene delivers up to 1E+17vg virus particles – enough to meet most commercial and clinical project requirements.